APLS - Gemini Therapeutics: Precision Medicine Company Focused On Dry AMD

• Gemini Therapeutics is bringing precision medicine and genomics to Dry AMD, a disease without an FDA-approved medicine.
• By focusing on CFH variants of Dry AMD, which represent over 6M patients in the US, the company is the first to bring a recombinant CFH into the clinic.
• Gemini's lead drug candidate, GEM103, is in phase 2 trials with a top line readout in the first half of 2021 and successive ones over the next 1-2 years.
• With a unique business model in AMD, Gemini is an exciting investment in a market leader with the potential to set the standard-of-care in Dry AMD.

For further details see: